Patents by Inventor Zhong Zhong
Zhong Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786503Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 7, 2021Date of Patent: October 17, 2023Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Patent number: 11739325Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: GrantFiled: August 7, 2018Date of Patent: August 29, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Jean-Cosme Dodart, Yuanjing Liu, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20220145300Abstract: Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating C9orf72-associated conditions, disorders or diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.Type: ApplicationFiled: May 8, 2020Publication date: May 12, 2022Inventors: Yuanjing Liu, Naoki Iwamoto, Chandra Vargeese, Zhong Zhong, Amy Jada Andreucci
-
Publication number: 20220133684Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 7, 2021Publication date: May 5, 2022Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Patent number: 11166936Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 6, 2020Date of Patent: November 9, 2021Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20210121436Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 6, 2020Publication date: April 29, 2021Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Publication number: 20210032620Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: ApplicationFiled: August 7, 2018Publication date: February 4, 2021Inventors: Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Jean-Cosme Dodart, Yuanjing Liu, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Patent number: 10874633Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: January 8, 2020Date of Patent: December 29, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20200362337Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: ApplicationFiled: August 7, 2018Publication date: November 19, 2020Inventors: Jean-Cosme Dodart, Yuanjing Liu, Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Patent number: 10806716Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: February 3, 2017Date of Patent: October 20, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20200253920Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: January 8, 2020Publication date: August 13, 2020Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Publication number: 20190175544Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: February 3, 2017Publication date: June 13, 2019Applicants: SCT II LLC, Auransa Inc.Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20180104930Abstract: This invention relates to clear, semicrystalline, strain induced crystallized polyester films heat laminated onto metal substrates. The films contain at least one polyester which comprises at least of one or more monomers selected from 1,4-cyclohexanedimethanol or 2,2,4,4-tetramethyl-1,3-cyclobutanediol. The articles of the present invention exhibit enhanced mechanical properties useful for the fabrication of thin metal articles such as metal cans.Type: ApplicationFiled: October 13, 2017Publication date: April 19, 2018Applicant: Eastman Chemical CompanyInventors: Xue Guang Steven Lin, Fan Liang Meng, Zhong Zhong Johnny Qian, Yu-Hwey Chuang, Emmett Dudley Crawford, Michael Eugene Donelson, Steven Lee Stafford, James Carl Williams
-
Publication number: 20170224654Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: February 3, 2017Publication date: August 10, 2017Applicants: Stem Cell Theranostics, Inc., Capella Biosciences, Inc.Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Patent number: 9445624Abstract: The present invention provides a composition of a plant material with anti-fatigue activity, its preparation method, usage and related products. The said composition is manufactured from the following plant materials: 20-80% from the genus Rhodiola; 10-60% Gynostemma; 10-60% Lycium. The said composition can be used to manufacture health product, food or anti-fatigue medicine which is able to significantly reduce the fatigue symptoms of those people suffering from fatigue, improve sleeping quality with no impact on normal body physiology. It is shown that the medicine derived from the present is invention exerts its anti-fatigue effect through improving the functions of erythrocytes and thrombocytes to enhance the body's ability of supplying oxygen. The medicinal composition of the present invention is characterized by the small effective dose and good water solubility and thus suitable to be made into a variety of dosage forms for use.Type: GrantFiled: August 5, 2010Date of Patent: September 20, 2016Inventors: Chen Xie, Zhong Zhong
-
Patent number: 9283256Abstract: The present invention relates to a selectively purified tanshinone compounds containing extract from the root of a Salvia spp comprising Cryptotanshinone, Dihydrotanshinone, Tanshinone I, and Tanshinone IIA. It comprises at least 15%, by weight of the said identified tanshinone compounds and at least 4% by weight, of cryptotanshinone. The extract and formulations thereof have been found to exhibit excellent anti-microbial properties against, in particular MRSA.Type: GrantFiled: October 14, 2008Date of Patent: March 15, 2016Assignee: Botanic Century (Beijing) Co. Ltd.Inventor: Zhong Zhong
-
Patent number: 8971488Abstract: Systems and methods for detecting an image of an object using a multi-beam imaging system from an x-ray beam having a polychromatic energy distribution are disclosed. According to one aspect, a method can include generating a first X-ray beam having a polychromatic energy distribution. Further, the method can include positioning a plurality of monochromator crystals in a predetermined position to directly intercept the first X-ray beam such that a plurality of second X-ray beams having predetermined energy levels are produced. Further, an object can be positioned in the path of the second X-ray beams for transmission of the second X-ray beams through the object and emission from the object as transmitted X-ray beams. The transmitted X-ray beams can each be directed at an angle of incidence upon one or more crystal analyzers. Further, an image of the object can be detected from the beams diffracted from the analyzer crystals.Type: GrantFiled: December 1, 2009Date of Patent: March 3, 2015Assignees: The University of North Carolina at Chapel Hill, NextRay, Inc., Brookhaven Science AssociatesInventors: Christopher A. Parham, Zhong Zhong, Etta Pisano, Dean M. Connor, Jr.
-
Publication number: 20140257157Abstract: In a casting apparatus for external skeletal and joint fixation, a plurality of articulated segments may comprise a plurality of cuboid members threaded on a continuous cord having distal ends connected to actuators. The cuboid members may be disposed between guide members threaded on the cord. Actuation of the actuators applies a tension force to the cord, thereby compressing the cuboid members together to form rigid cuboid segments and maintain the casting apparatus in a rigid configuration for skeletal and joint fixation.Type: ApplicationFiled: October 16, 2013Publication date: September 11, 2014Inventors: BING-TANG ZHONG, BING-ZHONG ZHONG, BING-ZHONG CHUNG
-
Patent number: 8724776Abstract: An x-ray focusing device and method for adjustably focusing x-rays in two orthogonal directions simultaneously. The device and method can be operated remotely using two pairs of orthogonal benders mounted on a rigid, open frame such that x-rays may pass through the opening in the frame. The added x-ray flux allows significantly higher brightness from the same x-ray source.Type: GrantFiled: September 8, 2011Date of Patent: May 13, 2014Assignee: Brookhaven Science Associates, LLCInventors: Edwin G. Haas, Christopher Stelmach, Zhong Zhong
-
Publication number: 20140057002Abstract: The present invention provides a composition of a plant material with anti-fatigue activity, its preparation method, usage and related products. The said composition is manufactured from the following plant materials: 20-80% from the genus Rhodiola; 10-60% Gynostemma; 10-60% Lycium. The said composition can be used to manufacture health product, food or anti-fatigue medicine which is able to significantly reduce the fatigue symptoms of those people suffering from fatigue, improve sleeping quality with no impact on normal body physiology. It is shown that the medicine derived from the present is invention exerts its anti-fatigue effect through improving the functions of erythrocytes and thrombocytes to enhance the body's ability of supplying oxygen. The medicinal composition of the present invention is characterized by the small effective dose and good water solubility and thus suitable to be made into a variety of dosage forms for use.Type: ApplicationFiled: August 5, 2010Publication date: February 27, 2014Inventors: Chen Xie, Zhong Zhong